Oracle Health Sciences has announced the results of a new study, conducted in partnership with Informa Engage, which reveals the top challenges and frustrations for clinical trial professionals with current Randomisation and Trial Supply Management/ Interactive Response Technology (RTSM/IRT) systems, as well as opportunities for improvement.
Among the many findings, the study revealed the top three challenges in RTSM/IRT for over 70% of respondents: integration with other platforms; slowness to build, test and deploy new trials; and lack of flexibility and inability to support study changes. The review and validation process is a further challenge.
Clinical trials are known for being complex and lengthy, and trial set up can account for a large portion of the time. Exploring the reasons for delay, the study found that 92% of respondents reported having to make changes to their RTSM/IRT systems due to study changes, and on an average of two times per study.
Given these results, it’s no wonder that over half of the respondents believe they could conduct more trials if they were able to leverage self-service capabilities to build new trials and make mid-study changes on their own.
“When you’re developing software to help people with a specific business process, such as clinical research, it’s important to stay in tune with the market to ensure you’re always innovating to address their top challenges and delighting them with a solution that makes their job easier,” says Steve Rosenberg, GM at Oracle Health Sciences.
“The findings from this research confirm the pain points that we address with our new Clinical One Randomisation and Supplies Management Cloud Service and that we are aligned with what the market wants in a modern RTSM/IRT solution.”
